Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections

The ongoing pandemic of coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Neutralizing antibodies against SARS-CoV-2 are an option for drug development for treating COVID-19. Here, we report the identification and characterization of two g...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chao, Wang, Yifan, Zhu, Yuanfei, Liu, Caixuan, Gu, Chenjian, Xu, Shiqi, Wang, Yalei, Zhou, Yu, Wang, Yanxing, Han, Wenyu, Hong, Xiaoyu, Yang, Yong, Zhang, Xueyang, Wang, Tingfeng, Xu, Cong, Hong, Qin, Wang, Shutian, Zhao, Qiaoyu, Qiao, Weihua, Zang, Jinkai, Kong, Liangliang, Wang, Fangfang, Wang, Haikun, Qu, Di, Lavillette, Dimitri, Tang, Hong, Deng, Qiang, Xie, Youhua, Cong, Yao, Huang, Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801428/
https://www.ncbi.nlm.nih.gov/pubmed/33431876
http://dx.doi.org/10.1038/s41467-020-20465-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801428/
https://www.ncbi.nlm.nih.gov/pubmed/33431876
http://dx.doi.org/10.1038/s41467-020-20465-w

Ejemplares similares